Why Thermo Fisher Scientific (TMO) is back in focus

Thermo Fisher Scientific (TMO) is drawing fresh attention as it reshapes its top leadership, closes a U.S. manufacturing site, and leans into new AI partnerships with NVIDIA and TetraScience around lab automation and data.

At a share price of US$618.72, Thermo Fisher has seen a 30 day share price return of 9.98% and a 90 day share price return of 14.81%, while the 1 year total shareholder return of 10.95% sits against leadership changes, facility closures and new AI focused partnerships that are reshaping how investors view its growth prospects and risks.

If developments in AI powered lab tools have caught your attention, it could be a good time to scan other healthcare stocks that are leaning into similar trends.

With Thermo Fisher shares at US$618.72, recent returns have been solid and the stock sits only slightly below the average analyst price target. The key question is whether there is still a buying opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 3.6% Undervalued

The most followed narrative places Thermo Fisher Scientific’s fair value at about US$641.57, slightly above the last close of US$618.72. This frames a modest undervaluation built on long term earnings and margin assumptions.

Ongoing strategic M&A and capacity expansion (e.g., Solventum acquisition), combined with resilient end-market exposure to pandemic preparedness, diagnostics, and emerging market healthcare investment, positions the company for compounding top-line gains and elevated returns on capital as secular demand trends accelerate.

Curious what kind of revenue runway, margin lift and future earnings multiple are baked into that fair value, and how they tie back to today’s price? The narrative spells out a detailed path using specific growth rates, profitability targets and a required return hurdle. If you want to see exactly how those moving parts line up, the full story is worth a closer look.

Result: Fair Value of $641.57 (UNDERVALUED)

However, it is worth keeping an eye on softer demand from academic and government customers and ongoing China related pressures, which could both weigh on the bullish case.

Another View: What Our DCF Says

While the popular narrative points to Thermo Fisher Scientific trading about 3.6% below its fair value of roughly US$641.57, our SWS DCF model is less optimistic. With a fair value estimate of about US$605.48 versus the current US$618.72 share price, the stock screens as slightly overvalued on this approach.

In practice, that gap is not huge, but it does change the risk reward balance. Instead of a small valuation cushion, the DCF view suggests you are paying a bit ahead of the modeled cash flows, which can matter if growth or margins end up closer to the low end of expectations. The question for you is which story you trust more: the earnings multiple based narrative or the cash flow math.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Thermo Fisher Scientific for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 863 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Thermo Fisher Scientific Narrative

If you see the numbers differently or prefer to weigh the assumptions yourself, you can stress test the data and Do it your way in just a few minutes.

A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Once you have formed a view on Thermo Fisher Scientific, do not stop there. Widen your watchlist with focused stock ideas built from clear, transparent data.

• Spot potential value plays early by checking out these 863 undervalued stocks based on cash flows that align with your return and risk filters.
• Ride major tech shifts by scanning these 24 AI penny stocks that are tied to long term AI adoption and data driven business models.
• Strengthen your income focus by reviewing these 12 dividend stocks with yields > 3% and seeing which companies match your yield and payout preferences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.